Systematic review and meta-analysis of second-generation antidepressants for the treatment of older adults with depression: questionable benefit and considerations for frailty

Abstract

BackgroundFrail older adults are commonly prescribed antidepressants. Yet, there is little evidence to determine the efficacy and safety of antidepressants to treat depression with concomitant frailty. To better understand this issue, we examined the efficacy and safety of second-generation antidepressants for the treatment of older adults with depression and then considered implications for frailty.MethodsDue to the absence of therapeutic studies of frail older adults with depression, we conducted a systematic review and meta-analysis of double-blind, randomized controlled trials that compared antidepressants versus placebo for adults with depression, age 65 years or older. We searched PubMed/MEDLINE, Cochrane Library, reference lists from meta-analyses/studies, hand searches of publication lists, and related articles on PubMed. Outcomes included rates of response, remission, and adverse events. After evaluating the data, we applied a frailty-informed framework to consider how the evidence could be applied to frailty.ResultsNine trials were included in the meta-analysis (n = 2704). Subjects had moderate to severe depression. For older adults with depression, there was no statistically significant difference in response or remission to second-generation antidepressants compared to placebo. Response occurred in 45.3% of subjects receiving an antidepressant compared to 40.5% receiving placebo (RR 1.15, 95% CI: 0.96 – 1.37, p = 0.12, I2 = 71%). Remission occurred in 33.1% with antidepressant versus 31.3% with placebo (RR 1.10, 95% CI: 0.92 – 1.31, p = 0.30, I2 = 56%) (Figure 2 and 3). There were more withdrawals due to adverse events with antidepressants, 13% versus 5.8% (RR 2.30, 95% CI: 1.45–3.63; p < 0.001; I2 = 61%; NNH 14, 95% CI:10–28).Implications for frailtySubjects in the meta-analysis did not have obvious characteristics of frailty. Using framework questions to consider the implications of frailty, we hypothesize that, like older adults, frail individuals with depression may not respond to antidepressants. Further, observational studies suggest that those who are frail may be less responsive to antidepressants compared to the non-frail. Given the vulnerability of frailty, adverse events may be more burdensome.ConclusionsSecond-generation antidepressants have uncertain benefit for older adults with depression and cause more adverse events compared to placebo. Until further research clarifies benefit, careful consideration of antidepressant prescribing with frailty is warranted.

Neuroimaging Indices Of Vascular Cognitive Impairment After Stroke In a Sample Of Egyptian Patients

“…Patient diagnosed ischemic or hemorrhagic stroke after 3 months from the event and their age not above 65 years old with no history of cognitive impairment before stroke 10 .…”

Phonotherapy – a new biological treatment proposal for the augmentation of pharmacotherapy in psychiatry and neurology

“…Pozostając w obszarze leczenia depresji, jedna z najnowszych metaanaliz wskazała również na ograniczoną skuteczność farmakologicznego leczenia depresji u starszych osób, u których w zasadzie nie ma statystycznie znamiennej różnicy pomiędzy leczeniem lekiem przeciwdepresyjnym i placebo. Dodatkowo sama skuteczność leczenia depresji w populacji starszych osób jest dwukrotnie mniejsza niż u osób we wczesnej i średniej dorosłości -wynosi 45,3% i 40,5% odpowiednio w grupie osób leczonych lekiem przeciwdepresyjnym lub placebo [2].…”

“…In the field of treating depression, one of the most recent metaanalyses showed a limited efficacy of pharmacological treatment of depression in older patients, for whom there is virtually no statistically significant difference between the treatment with an antidepressant and a placebo. Additionally, the effectiveness of treating depression in the elderly population is twice as low as in people in early and middle adulthood, and is 45.3% and 40.5% in the group of people treated with an antidepressant or a placebo, respectively [2].…”

Tolerability and Efficacy of Vortioxetine Versus SSRIs in Elderly With Major Depression. Study Protocol of the VESPA Study: A Pragmatic, Multicentre, Open-Label, Parallel-Group, Superiority, Randomized Trial

“…Other antidepressants, such as tricyclic antidepressants (TCAs), serotonin and norepinephrine reuptake inhibitors (SNRIs) and mirtazapine are associated with a similar or higher risk of a number of adverse events, including sedation, confusion, urinary retention, cardiovascular and gastrointestinal issues [16], and are generally avoided in these patients. Moreover, the magnitude of beneficial effects of antidepressants in late-life depression has been questioned [17], making it hard for clinicians to accurately balance benefits and risks.…”